Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study-Reference-Cited by-同舟云学术

Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study

Published:2024-06-27 Issue:8 Volume:14 Page:2077-2092
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Korge Bernhard,Vanhooteghem Olivier,Lynde Charles W.,Machovcova Alena,Perrussel Marc,Lazaridou Elisavet,Marasca Claudio,Sarro David Vidal,Pousa Ines Duenas,Fierens Frederik,Williams Paulette,Shimizu Saori,Heidbrede Tanja,Warren Richard B.

Funder

UCB Pharma

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01210-3.pdf

Reference35 articles.

1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301–15.

2. Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8: 743180.

3. Crochard A, Gherardi A, Hueber Kollen M, Issa S, Villani A. Assessing the burden of patients with psoriasis through the concept of cumulative life course impairment: a narrative literature review. JEADV Clin Pract. 2023;2:423–31.

4. Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists’ Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183:628–37.

5. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–72.